Table 4 Patient-reported outcomes
Patient-Reported Outcomes | LASAα, β HBCS€ CTCAE-PRO‡ | Baseline (n = 70) | Post-RT (n = 64) | 3 month (n = 56) | 12 month (n = 41) |
|---|---|---|---|---|---|
Quality of Life α | 7–10 | 90% | 92% | 93% | 93% |
4–6 | 8% | 6% | 3% | 7% | |
1–3 | 2% | 2% | 3% | – | |
Skin Toxicity‡ | None | 100% | 75% | 86% | 90% |
Mild | 0% | 23% | 14% | 10% | |
Moderate | 0% | 9% | 2% | 5% | |
Severe/very severe | 0% | 0% | 0% | 0% | |
Pain β | 1–3 | 86% | 91% | 84% | 88% |
4–6 | 13% | 6% | 16% | 10% | |
7–10 | 1% | 3% | 0% | 2% | |
Fatigue β | 1–3 | 79% | 73% | 73% | 73% |
4–6 | 13% | 14% | 16% | 20% | |
7–10 | 9% | 13% | 11% | 7% | |
Breast Cosmesis€ | Excellent | 43% | 63% | 62% | 71% |
Good | 50% | 27% | 36% | 27% | |
Fair | 5% | 9% | 2% | 2% | |
Poor | 2% | 2% | 0% | 0% |